Hanx Biopharmaceuticals Calls 24 Jun 2026 AGM to Vote on 2025 Results, 20% Issuance Mandate and 10% H-Share Buyback

Bulletin Express06-02

Hanx Biopharmaceuticals (HANXBIO-B) has scheduled its Annual General Meeting (AGM) for 10:00 a.m. on 24 June 2026 at the company’s Wuhan headquarters. Shareholders will vote on a total of ten resolutions—seven ordinary and three special—covering financial statements, capital mandates and governance updates.

Key ordinary items • Approval of the Board Report, Supervisors Committee Report and full Annual Report for FY 2025. • Endorsement of the FY 2025 final financial statements alongside the FY 2026 budget. • Re-appointment of Ernst & Young as auditor for FY 2026, with the Board authorised to set remuneration. • Ratification of the directors’ remuneration plan for 2026. • Approval of the 2025 profit-distribution proposal (details not disclosed in the notice).

Special resolutions on capital management 1. Articles of Association amendments. 2. General mandate authorising the Board to issue, allot or deal with additional shares—excluding treasury shares—up to 20% of the company’s issued share capital as at the AGM date. The mandate extends to rights issues, option exercise and scrip dividends, and remains valid until the next AGM or earlier revocation. 3. Authority to repurchase up to 10% of outstanding H-shares during the same mandate period. The Board may cancel or hold repurchased shares as treasury stock and adjust registered capital accordingly.

Shareholder logistics • H-share register will close from 18 June 2026 to 24 June 2026, inclusive. Transfers must be lodged by 4:30 p.m. on 17 June 2026 to qualify for AGM attendance and voting. • Proxy forms must reach Tricor Investor Services by 10:00 a.m. on 23 June 2026. • All AGM resolutions will be decided by poll, with results posted on the HKEX and company websites.

Board composition As of the notice date, the Board comprises four executive directors, one non-executive director and four independent non-executive directors, chaired by Dr. Zhang Faming.

The AGM outcomes will guide Hanx Biopharmaceuticals’ capital structure and corporate governance for the forthcoming fiscal year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment